iShares NASDAQ Biotechnology Index (IBB) Shares Bought by SOL Capital Management CO

SOL Capital Management CO boosted its holdings in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 200.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 20,022 shares of the financial services provider’s stock after purchasing an additional 13,348 shares during the quarter. SOL Capital Management CO’s holdings in iShares NASDAQ Biotechnology Index were worth $2,138,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. CHURCHILL MANAGEMENT Corp increased its holdings in shares of iShares NASDAQ Biotechnology Index by 223.2% during the fourth quarter. CHURCHILL MANAGEMENT Corp now owns 1,801,330 shares of the financial services provider’s stock valued at $192,328,000 after acquiring an additional 1,244,066 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of iShares NASDAQ Biotechnology Index by 175.5% during the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 635,875 shares of the financial services provider’s stock valued at $212,132,000 after acquiring an additional 405,091 shares in the last quarter. Lockheed Martin Investment Management Co. increased its holdings in shares of iShares NASDAQ Biotechnology Index by 200.0% during the fourth quarter. Lockheed Martin Investment Management Co. now owns 329,400 shares of the financial services provider’s stock valued at $35,170,000 after acquiring an additional 219,600 shares in the last quarter. Commerzbank Aktiengesellschaft FI increased its holdings in shares of iShares NASDAQ Biotechnology Index by 159.9% during the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 294,237 shares of the financial services provider’s stock valued at $31,416,000 after acquiring an additional 181,036 shares in the last quarter. Finally, IFG Advisory LLC bought a new stake in shares of iShares NASDAQ Biotechnology Index during the fourth quarter valued at approximately $637,000. Institutional investors and hedge funds own 24.09% of the company’s stock.

Shares of iShares NASDAQ Biotechnology Index (IBB) opened at $114.08 on Thursday. iShares NASDAQ Biotechnology Index has a 1-year low of $89.19 and a 1-year high of $119.30.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.com-unik.info/2018/02/01/ishares-nasdaq-biotechnology-index-ibb-shares-bought-by-sol-capital-management-co.html.

iShares NASDAQ Biotechnology Index Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares NASDAQ Biotechnology Index (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit